Risk-adjusted comparison of survival in chronic myelomonocytic leukemia with and without allogeneic stem cell transplant: Mayo Clinic experience in 775 consecutive patients
Retrospective analysis shows longer overall survival in chronic myelomonocytic leukemia with allogeneic stem cell transplant, indicating significant benefits across risk categories.
Key Points
Overall survival was significantly longer in chronic myelomonocytic leukemia patients undergoing stem cell transplant than those who did not.
The median survival for transplant patients reached 77 months compared to 28 months for the non-transplant group, with a hazard ratio of 0.3 (p<0.01).
Statistical analyses were conducted using JMP Pro 17.1.0, facilitating a comprehensive examination of transplant effectiveness.
These findings suggest early allogeneic stem cell transplant may provide critical benefits for chronic myelomonocytic leukemia patients regardless of genetic factors.